TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37588266
Drug: Empiric dosing
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric dosing of fibrinogen concentrate
Study: 37588667
Drug: Daily electronically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily electronically recorded patient-reported outcomes (ePROs) on the presence of MG symptoms, level of symptom severity (MG-ADL), and exacerbation status.
Study: 37588667
Drug: Self-reported MG-ADL
Normalized name: Adlyxin
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Self-reported MG-ADL scores during exacerbation periods.
Study: 37588667
Drug: Self-reported MG-ADL
Normalized name: Adlyxin
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Self-reported MG-ADL scores during non-exacerbation periods.
Study: 37588667
Drug: Dynamic changes
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic changes in day-to-day symptom reporting and severity, daily step counts, clinical characteristics.
Study: 37589641
Drug: Multiphase SCS
Normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiphase SCS therapy A (approximately 600-1500 Hz)
Study: 37589641
Drug: Multiphase SCS
Normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiphase SCS therapy B (approximately 300-600 Hz)
Study: 37589641
Drug: Commercial SCS
Normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial SCS therapy
Study: 37589639
Drug: Autologous IFNγ-stimulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous IFNγ-stimulated MSC(M) injection into submandibular gland
Study: 37589639
Drug: Autologous IFNγ-stimulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous IFNγ-stimulated MSC(M) injection
Study: 37589642
Drug: Repetitive Transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) of the motor cortex targeting the painful limb, administered over five months
Study: 37589748
Drug: Mandibular advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular advancement device (MAD) therapy
Study: 37589748
Drug: MAD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAD therapy
Study: 37589932
Drug: IPL +
Normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPL + DQS therapy
Study: 37589932
Drug: IPL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPL therapy
Study: 37590001
Drug: Anticancer agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticancer agents targeting AMPK
Study: 37591292
Drug: Nefecon (targeted-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefecon (targeted-release formulation of budesonide)
Study: 37591293
Drug: Cemiplimab 350
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 350 mg every 3 weeks for up to 108 weeks
Study: 37591293
Drug: Cemiplimab plus
Normalized name: cemiplimab
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab plus chemotherapy (as second-line therapy)
Study: 37591308
Drug: Treatment concepts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment concepts converting DMD to BMD phenotype
Study: 37591454
Drug: 7-item Satisfaction
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-item Satisfaction with Treatment
Study: 37591633
Drug: Tocilizumab (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (280 mg single dose)
Study: 37591655
Drug: 4.2% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.2% sodium bicarbonate infusion to target a plasma pH ≥ 7.30
Study: 37591655
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no sodium bicarbonate infusion)
Study: 37591655
Drug: 4.2% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.2% sodium bicarbonate infusion
Study: 37592092
Drug: Bosutinib 300
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib 300 mg QD (step-in dosing)
Study: 37592092
Drug: Bosutinib 400
Normalized name: bosutinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 400 mg QD (approved first-line dose)
Study: 37592092
Drug: Bosutinib 500
Normalized name: bosutinib 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 500 mg QD (approved later-line dose)
Study: 37592104
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipilimumab and nivolumab
Study: 37592217
Drug: Standard speech
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard speech therapy remediation
Study: 37592263
Drug: Inhalation technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation technique errors 'Breathe in', 'Hold breath', 'Breathe out calmly after inhalation'
Study: 37592263
Drug: Inhalation technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation technique errors 'Preparation', 'Hold inhaler in correct position during inhalation', 'Breathe in'
Study: 37592263
Drug: Overall inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall inhalation technique errors
Study: 37592263
Drug: Specific combinations
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific combinations of inhalation technique errors
Study: 37592263
Drug: Increasing inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing inhalation technique error count
Study: 37592358
Drug: Music intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Music intervention (twice daily for three days, at least 30 min per session)
Study: 37592403
Drug: 2.5 mL
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL of 40% ethanol per kg body weight via a nasogastric tube
Study: 37592860
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) combined with language therapy
Study: 37592860
Drug: Language treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Language treatment alone (Control)
Study: 37593221
Drug: sintilimab plus
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sintilimab plus bevacizumab (200 mg and 7.5 mg/kg respectively, intravenously every 3 weeks)
Study: 37593227
Drug: AK112 combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK112 combined with pemetrexed (500 mg/m2) in cohort 1 (previously untreated)
Study: 37593227
Drug: AK112 combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK112 combined with chemotherapy in cohort 2 (EGFR-functional mutation)
Study: 37593227
Drug: AK112 combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK112 combined with chemotherapy in cohort 3 (failed prior systemic treatments)
Study: 37593752
Drug: feladilimab (anti-ICOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: feladilimab (anti-ICOS mAb) + pembrolizumab (PD-1 inhibitor)
Study: 37593838
Drug: DWP16001 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 (2 mg)
Study: 37593838
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DWP16001 and phentermine
Study: 37593881
Drug: Vimseltinib 30
Normalized name: vimseltinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vimseltinib 30 mg twice weekly for up to 24 weeks
Study: 37594044
Drug: Mirikizumab 200
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirikizumab 200 mg subcutaneous every 4 or 12 weeks through week 52
Study: 37594769
Drug: Algorithmic approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithmic approach to ventilator withdrawal; details on dosage and duration not available.
Study: 37594769
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care for ventilator withdrawal; details on dosage and duration not available.
Study: 37594946
Drug: Play-based, parent-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Play-based, parent-delivered intervention focusing on regaining pre-treatment mobility and midline crossing until 7 weeks post-treatment, individualized from 7 weeks to 6 months post-treatment.
Study: 37595103
Drug: Baloxavir marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baloxavir marboxil (single-dose)
Study: 37595103
Drug: Oseltamivir (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (twice-daily for 5 days)
Study: 37596281
Drug: Intranasal adenoviral
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal adenoviral vectored SARS-CoV-2 vaccine (BBV154)
Study: 37596281
Drug: Licensed intramuscular
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed intramuscular vaccine, Covaxin
Study: 37596280
Drug: CoVac-1 (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoVac-1 (one subcutaneous dose)
Study: 37596449
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with complete cytoreduction (CC-0)
Study: 37596658
Drug: carbon suspension
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: carbon suspension
Study: 37596658
Drug: clip + iodine seed,
Approvals — FDA: no, EMA: no, PMDA: no
Description: clip + iodine seed, magnetic seed, carbon suspension
Study: 37597153
Drug: Idecabtagene vicleucel
Normalized name: idecabtagene vicleucel
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idecabtagene vicleucel (ide-cel) treatment
Study: 37597159
Drug: Guselkumab (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab (subcutaneous 100 mg at weeks 0, 4, and every 8 weeks)
Study: 37597246
Drug: Binimetinib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib (45 mg twice daily) plus Panitumumab (6 mg/kg every 2 weeks)
Study: 37597326
Drug: Adjunctive brivaracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive brivaracetam (BRV) treatment
Study: 37597523
Drug: Levonorgestrel 1.5
Normalized name: levonorgestrel 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 1.5 mg plus piroxicam 40 mg
Study: 37597523
Drug: Levonorgestrel 1.5
Normalized name: levonorgestrel 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 1.5 mg plus placebo
Study: 37597969
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg BI 1015550
Study: 37597969
Drug: 18 mg
Normalized name: niacin 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg BI 1015550
Study: 37597969
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (9 mg, 18 mg, placebo)
Study: 37598795
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose as treatment for heart failure with iron deficiency
Study: 37598795
Drug: HFrEF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFrEF therapy including beta-blocker
Study: 37598795
Drug: HFrEF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFrEF therapy including ARNI
Study: 37598795
Drug: HFrEF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFrEF therapy including MRA
Study: 37599908
Drug: Parsaclisib 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib 2.5 mg QD (daily dosing group)
Study: 37599908
Drug: Parsaclisib 20
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib 20 mg QD for 8 weeks, then either 20 mg once-weekly or 2.5 mg QD
Study: 37600550
Drug: Quercetin aglycone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin aglycone 250 mg
Study: 37600550
Drug: Quercetin aglycone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin aglycone 500 mg
Study: 37600550
Drug: Quercetin aglycone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin aglycone 1000 mg
Study: 37600800
Drug: 1/10 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/10 dose of Sputnik V vaccine
Study: 37600800
Drug: 1/5 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/5 dose of Sputnik V vaccine
Study: 37600876
Drug: Hyperinsulinemic-normoglycemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic-normoglycemic clamp (HNC) initiated by infusing insulin at 2 mU/kg/min and administering dextrose to maintain normoglycemia (4.0-6.0 mmol/L).
Study: 37600959
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all three tests (PSE, ANT, CFF)
Study: 37601010
Drug: Romiplostim (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romiplostim (1 to 10 μg/kg for 9 weeks)
Study: 37601885
Drug: Quadruplet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruplet therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone) followed by autologous hematopoietic cell transplantation (AHCT)
Study: 37602376
Drug: FFR-guided PCI
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFR-guided PCI using zotarolimus drug-eluting stents
Study: 37602458
Drug: Genotyping group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotyping group (high-risk subgroup received candesartan 8 mg/day for 6 weeks; low-risk subgroup received perindopril 4 mg/day)
Study: 37602458
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not genotyped, received perindopril 4 mg/day)
Study: 37603328
Drug: Teriflunomide, 14
Normalized name: Teriflunomide, 14 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriflunomide, 14 mg daily
Study: 37603835
Drug: Treat-to-target strategy
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target strategy with pan-enteric capsule endoscopy (PCE)
Study: 37604637
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of prophylactic antibiotics administered within 24 hours
Study: 37604637
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of prophylactic antibiotics administered within 24 hours
Study: 37604637
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of prophylactic antibiotics
Study: 37604637
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of prophylactic antibiotics
Study: 37604662
Drug: Metoclopramide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide + 4 mg dexamethasone
Study: 37604662
Drug: Metoclopramide +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide + 16 mg dexamethasone
Study: 37604662
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone (4 mg)
Study: 37604662
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (16 mg)
Study: 37604981
Drug: Glasdegib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib plus intensive chemotherapy (cytarabine and daunorubicin)
Study: 37604981
Drug: Glasdegib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib plus non-intensive chemotherapy (azacitidine)
Study: 37604988
Drug: FUS-MB treatment
Normalized name: Ionosol-MB
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUS-MB treatment delivered before 1st and 5th fractions of RT (within 1 hour)
Study: 37606364
Drug: Oral lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lipid nanocrystal (LNC) amphotericin B + flucytosine (1.8 g/d for 2 weeks, then 1.2 g/d for 6 weeks)
Study: 37606364
Drug: Oral lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lipid nanocrystal (LNC) amphotericin B with IV loading doses + flucytosine
Study: 37606606
Drug: CBD daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD daily in cycle 1
Study: 37606641
Drug: Regorafenib (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib (starting dose 72 mg/m2/day) with vincristine (1.5 mg/m2 on days 1 and 8) and irinotecan (50 mg/m2 on days 1-5)
Study: 37606641
Drug: Regorafenib (MTD/RP2D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib (MTD/RP2D of 82 mg/m2 in sequential schedule)
Study: 37606672
Drug: EC-IC bypass
Normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC-IC bypass surgery plus medical therapy (surgical group; n=161)
Study: 37606672
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone (medical group; n=163)
Study: 37606856
Drug: Neurotropic infections
Normalized name: brain-derived neurotrophic factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurotropic infections (viral, bacterial, protozoal) assessed through serology testing in patients treated with immune checkpoint inhibitors (ICI).
Study: 37607096
Drug: Chimeric Antigen
Normalized name: Chimeric antigen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric Antigen Receptor T Cell Manufacturing using CliniMACS Prodigy
Study: 37607203
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (BLT) for 30 minutes each morning for 3-4 weeks
Study: 37607457
Drug: Non-HCT treatment
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-HCT treatment
Study: 37607644
Drug: Propylene glycol-free
Normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propylene glycol-free melphalan (PGF-Mel) at 140 to 200 mg/m²
Study: 37607780
Drug: Anifrolumab intensified
Normalized name: anifrolumab
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anifrolumab intensified regimen (IR) 900 mg for the first 3 doses followed by 300 mg every 4 weeks
Study: 37607780
Drug: Anifrolumab basic
Normalized name: anifrolumab
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anifrolumab basic regimen (BR) 300 mg every 4 weeks
Study: 37607809
Drug: Tapering TNFi
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering TNFi to discontinuation
Study: 37608269
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml group (ESB with 10 ml of bupivacaine 0.5%, 1 ml of methylprednisolone, 2 ml of non-ionic contrast, and 7 ml of saline 0.9%)
Study: 37608269
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml group (ESB with 15 ml of bupivacaine 0.5%, 1 ml of methylprednisolone, 2 ml of non-ionic contrast, and 12 ml of saline 0.9%)
Study: 37608287
Drug: Invimestrocel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invimestrocel plus standard treatment
Study: 37608315
Drug: Amantadine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine administered intravenously for five days at a dosage of 100 mg bid.
Study: 37608315
Drug: Amantadine (if
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (if non-responders, dosage doubled from day three to five).
Study: 37608315
Drug: Amantadine treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine treatment.
Study: 37608909
Drug: Pressure biofeedback-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure biofeedback-guided DCFM strength training and conventional treatment
Study: 37608909
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and conventional treatment
Study: 37609003
Drug: Dodecafluoropentane emulsion
Normalized name: dodecafluoropentane emulsion (DDFPe)
DrugBank: Perflenapent (DB11625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dodecafluoropentane emulsion (DDFPe) administered via intravenous infusion at doses of 0.05, 0.10, or 0.17 mL/kg while breathing supplemental oxygen prior to each 2 Gy fraction of radiotherapy (30 fractions over 6 weeks) along with standard-of-care chemotherapy (temozolomide).
Study: 37609003
Drug: Dodecafluoropentane emulsion
Normalized name: dodecafluoropentane emulsion (DDFPe)
DrugBank: Perflenapent (DB11625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dodecafluoropentane emulsion (DDFPe) administered at 0.1 mL/kg dose level.
Study: 37609318
Drug: Brief Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Cognitive Behavioral Therapy
Study: 37609358
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of high-dose vs low-dose treprostinil
Study: 37609651
Drug: First-line anti-seizure
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line anti-seizure medications (ASMs) as substitution therapy
Study: 37609651
Drug: Second-line anti-seizure
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line anti-seizure medications (ASMs)
Study: 37609698
Drug: Cangrelor at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cangrelor at the start of PCI plus prasugrel at the end of infusion
Study: 37609714
Drug: Neoadjuvant pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant pertuzumab and trastuzumab fixed-dose combination administered subcutaneously plus taxane-based chemotherapy